Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain

[1]  程超,et al.  68 Ga-PSMA-11 PET-CT与全身磁共振成像诊断前列腺癌远处转移的效能比较 , 2021 .

[2]  B. Slusher,et al.  Enhanced oral bioavailability of 2-(phosphonomethyl)-pentanedioic acid (2-PMPA) from its (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL) based prodrugs. , 2019, Molecular pharmaceutics.

[3]  D. Mahalingam,et al.  A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma , 2019, Cancers.

[4]  U. Lützen,et al.  Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma , 2019, Nuklearmedizin.

[5]  S. Marie,et al.  Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer , 2019, Cell reports.

[6]  P. Albers,et al.  Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  C. Uprimny.  68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging? , 2019, Wiener Medizinische Wochenschrift.

[8]  A. Paschali,et al.  Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer. , 2019, Clinical nuclear medicine.

[9]  K. Lemberg,et al.  We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine , 2018, Molecular Cancer Therapeutics.

[10]  Matthias Eiber,et al.  68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging , 2018, The Journal of Nuclear Medicine.

[11]  J. Kotzerke,et al.  Prostate-Specific Membrane Antigen Expression in Distal Radius Fracture. , 2018, Clinical nuclear medicine.

[12]  D. O’Keefe,et al.  A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies , 2018, The Journal of Nuclear Medicine.

[13]  Rajender Kumar,et al.  Synchronous Detection of Male Breast Cancer and Prostatic Cancer in a Patient With Suspected Prostatic Carcinoma on 68Ga-PSMA PET/CT Imaging. , 2018, Clinical nuclear medicine.

[14]  G. Arora,et al.  68Ga-Prostate-Specific Membrane Antigen PET/CT in Triple-Negative Breast Cancer. , 2018, Clinical nuclear medicine.

[15]  D. Murphy,et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[16]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter? , 2018, The Journal of Nuclear Medicine.

[17]  U. Haberkorn,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control , 2018, The Journal of Nuclear Medicine.

[18]  G. Kristiansen,et al.  Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy , 2018, Breast Cancer Research and Treatment.

[19]  K. Rahbar,et al.  Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  H. Hieronymus,et al.  Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors , 2018, The Journal of experimental medicine.

[21]  Alexander Haug,et al.  Current status of theranostics in prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  T. Joensuu,et al.  Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  K. Miles,et al.  Subacute Cerebellar Infarction With Uptake on 68Ga-Prostate-Specific Membrane Antigen PET/CT. , 2017, Clinical nuclear medicine.

[24]  G. Lenz,et al.  Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer , 2017, PloS one.

[25]  Martin C. Wright,et al.  Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression , 2017, The Journal of Nuclear Medicine.

[26]  L. Ensign,et al.  Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Steven P Rowe,et al.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.

[28]  B. Slusher,et al.  Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs. , 2017, Molecular pharmaceutics.

[29]  G. Antoch,et al.  Evaluation of Practical Interpretation Hurdles in 68Ga-PSMA PET/CT in 55 Patients: Physiological Tracer Distribution and Incidental Tracer Uptake , 2017, Clinical nuclear medicine.

[30]  R. Mansberg,et al.  Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor. , 2017, Clinical nuclear medicine.

[31]  Matthias Eiber,et al.  177Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[32]  H. Zacho,et al.  68Ga-PSMA PET/CT Uptake in Intramuscular Myxoma Imitates Prostate Cancer Metastasis. , 2017, Clinical nuclear medicine.

[33]  H. Demir,et al.  Uptake of an Acrochordon Incidentally Detected on 68Ga Prostate-Specific Membrane Antigen PET/CT. , 2017, Clinical nuclear medicine.

[34]  Koen Van Laere,et al.  Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  W. Weichert,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.

[36]  Johan De Mey,et al.  PSMA Uptake in Mediastinal Sarcoidosis. , 2017, Clinical nuclear medicine.

[37]  E. Hsiao,et al.  Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA PET/CT. , 2017, Clinical nuclear medicine.

[38]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.

[39]  B. Slusher,et al.  Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors. , 2016, Advances in pharmacology.

[40]  K. Rahbar,et al.  Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST , 2016, Oncotarget.

[41]  P. Choyke,et al.  PSMA PET and Radionuclide Therapy in Prostate Cancer. , 2016, Seminars in nuclear medicine.

[42]  A. Sasikumar,et al.  Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. , 2016, Nuclear medicine and biology.

[43]  R. Bohle,et al.  Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases , 2017, Clinical & Experimental Metastasis.

[44]  T. Maurer,et al.  68Ga-PSMA PET/MR Showing Intense PSMA Uptake in Nodular Fasciitis Mimicking Prostate Cancer Metastasis. , 2016, Clinical nuclear medicine.

[45]  U. Haberkorn,et al.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[46]  A. Sasikumar,et al.  68Ga-PSMA PET/CT False-Positive Tracer Uptake in Paget Disease. , 2016, Clinical nuclear medicine.

[47]  K. Rahbar,et al.  Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[48]  Sait Sağer,et al.  Incidental Detection of Follicular Thyroid Carcinoma in 68Ga-PSMA PET/CT Imaging , 2016, The Journal of Nuclear Medicine Technology.

[49]  M. Marohn,et al.  FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. , 2016, JCI insight.

[50]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[51]  M. Ghosh,et al.  Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide , 2016, Angiogenesis.

[52]  Lode Goethals,et al.  Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68Ga-PSMA PET/CT. , 2016, Clinical nuclear medicine.

[53]  T. Eade,et al.  Desmoid Tumor Showing Intense Uptake on 68Ga PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[54]  C. Bal,et al.  PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer? , 2016, Clinical nuclear medicine.

[55]  O. Boerman,et al.  Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent , 2016, Theranostics.

[56]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[57]  D. Maintz,et al.  Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis. , 2015, Clinical nuclear medicine.

[58]  E. Demirci,et al.  Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[59]  A. Sawa,et al.  Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration , 2015, PloS one.

[60]  Yi Pan,et al.  Expression of Prostate-Specific Membrane Antigen in Lung Cancer Cells and Tumor Neovasculature Endothelial Cells and Its Clinical Significance , 2015, PloS one.

[61]  F. Mottaghy,et al.  First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[62]  U. Haberkorn,et al.  PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[63]  J. Konvalinka,et al.  Structural and biochemical characterization of the folyl‐poly‐γ‐l‐glutamate hydrolyzing activity of human glutamate carboxypeptidase II , 2014, The FEBS journal.

[64]  B. Ristau,et al.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. , 2014, Urologic oncology.

[65]  S. Pastorino,et al.  Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases , 2014, Cancer Cell International.

[66]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[67]  Huan Zhang,et al.  Prostate-specific membrane antigen as a marker of pancreatic cancer cells , 2014, Medical Oncology.

[68]  S. Ben-Shachar,et al.  Gene Expression Profiles of Ileal Inflammatory Bowel Disease Correlate with Disease Phenotype and Advance Understanding of Its Immunopathogenesis , 2013, Inflammatory bowel diseases.

[69]  L. Shapiro,et al.  Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2 , 2013, Angiogenesis.

[70]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[71]  T. Dassopoulos,et al.  An Ileal Crohn's Disease Gene Signature Based on Whole Human Genome Expression Profiles of Disease Unaffected Ileal Mucosal Biopsies , 2012, PloS one.

[72]  J. Konvalinka,et al.  GCPII variants, paralogs and orthologs. , 2012, Current medicinal chemistry.

[73]  M. Pomper,et al.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. , 2012, Current medicinal chemistry.

[74]  Jack Satsangi,et al.  Characterization of intestinal gene expression profiles in Crohn's disease by genome‐wide microarray analysis , 2010, Inflammatory bowel diseases.

[75]  J. Konvalinka,et al.  Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III , 2009, The FEBS journal.

[76]  Victor E Reuter,et al.  Prostate-specific membrane antigen expression in regeneration and repair , 2008, Modern Pathology.

[77]  G. V. van Leenders,et al.  Histopathological and immunohistochemical characterization of canine prostate cancer , 2008, The Prostate.

[78]  J. McArthur,et al.  Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. , 2007, Brain : a journal of neurology.

[79]  S. Vollset,et al.  Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study. , 2007, The American journal of clinical nutrition.

[80]  Rolf Hilgenfeld,et al.  Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. , 2007, Acta crystallographica. Section D, Biological crystallography.

[81]  J. Konvalinka,et al.  A high-resolution structure of ligand-free human glutamate carboxypeptidase II. , 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

[82]  Dianqing Wu,et al.  Prostate-Specific Membrane Antigen Regulates Angiogenesis by Modulating Integrin Signal Transduction , 2006, Molecular and Cellular Biology.

[83]  S. Landas,et al.  Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues , 2006, World Journal of Surgery.

[84]  A. Devlin,et al.  Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. , 2006, The American journal of clinical nutrition.

[85]  D. Hilt,et al.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. , 2005, British journal of clinical pharmacology.

[86]  D. Hunter,et al.  Polymorphisms in the one‐carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study , 2004, International journal of cancer.

[87]  H. Blom,et al.  Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C-->T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk. , 2002, Atherosclerosis.

[88]  P. Wilson,et al.  The glutamate carboxypeptidase gene II (C>T) polymorphism does not affect folate status in the Framingham Offspring cohort. , 2002, The Journal of nutrition.

[89]  A. D. Smith,et al.  Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. , 2000, Human molecular genetics.

[90]  I. Black,et al.  Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system , 1999, The Journal of comparative neurology.

[91]  F. Tortella,et al.  Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury , 1999, Nature Medicine.

[92]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[93]  J. Coyle,et al.  Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II 1 Published on the World Wide Web on 24 April 1998. 1 , 1998, Brain Research.

[94]  J. Coyle,et al.  Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[95]  J. Neale,et al.  Molecular Cloning of a Peptidase Against N‐Acetylaspartylglutamate from a Rat Hippocampal cDNA Library , 1997, Journal of neurochemistry.

[96]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[97]  B. Suffoletto,et al.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  J. Coyle,et al.  Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[99]  L. E. Ross,et al.  Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. , 1996, Journal of medicinal chemistry.

[100]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[101]  J. Coyle,et al.  N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system , 1995, Journal of neurocytology.

[102]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[103]  W. Fair,et al.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.

[104]  J. Coyle,et al.  Immunocytochemical localization of the N‐acetyl‐aspartyl‐glutamate (NAAG) hydrolyzing enzyme N‐acetylated α‐linked acidic dipeptidase (NAALADase) , 1992, The Journal of comparative neurology.

[105]  J. Coyle,et al.  Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. , 1990, The Journal of biological chemistry.

[106]  J. Coyle,et al.  Hydrolysis of the Brain Dipeptide N‐Acetyl‐l‐Aspartyl‐l‐Glutamate: Subcellular and Regional Distribution, Ontogeny, and the Effect of Lesions on N‐Acetylated‐α‐Linked Acidic Dipeptidase Activity , 1988, Journal of neurochemistry.

[107]  J. Coyle,et al.  Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. , 1987, The Journal of biological chemistry.

[108]  J. Coyle,et al.  Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. , 1986, European journal of pharmacology.

[109]  J. Coyle,et al.  N-Acetylaspartylglutamate: possible role as the neurotransmitter of the lateral olfactory tract. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[110]  B. Shane,et al.  Availability of monoglutamyl and polyglutamyl folates in normal subjects and in patients with coeliac sprue. , 1978, Gut.

[111]  C. Butterworth,et al.  Jejunal perfusion of simple and conjugated folates in man. , 1975, Gastroenterology.

[112]  L. Fry,et al.  Malabsorption of Dietary Folate (Pteroylpolyglutamates) in Adult Coeliac Disease and Dermatitis Herpetiformis , 1970, British medical journal.

[113]  K. Bouchelouche,et al.  68Ga-PSMA Uptake in Anal Fistula on PET/CT Scan. , 2019, Clinical nuclear medicine.

[114]  K. Rahbar,et al.  Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017 .

[115]  Kratochwil Clemens,et al.  Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Dosimetry estimate and empirical dose finding , 2017 .

[116]  R. Velthoven,et al.  Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[117]  M. Schwaiger,et al.  Intense PSMA-expression using 68Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[118]  U. Haberkorn,et al.  Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[119]  G. Tabatabai,et al.  In vivo visualization of prostate-specific membrane antigen in glioblastoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[120]  J. A. Dar,et al.  Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women. , 2008, International journal of health sciences.

[121]  H. Blom,et al.  The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans. , 2003, The Journal of nutrition.

[122]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[123]  G. Murphy,et al.  Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356) , 1991, The Prostate.

[124]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.

[125]  J. Coyle,et al.  Acidic peptides in brain: do they act at putative glutamatergic synapses? , 1986, Advances in experimental medicine and biology.